Biogen Idec Ramps Up For BG-12, Dubs The MS Drug Tecfidera
This article was originally published in The Pink Sheet Daily
The biopharma released the new name and cited a rough pricing range for multiple sclerosis drug BG-12, which has a late March PDUFA date. But management tapped the brakes a bit on analyst sales estimates, offering a few words of caution.
You may also be interested in...
The company expects dimethyl fumarate’s strong efficacy and favorable safety and tolerability profile to be an advantage against other oral multiple sclerosis drugs.
FDA approved the oral multiple sclerosis drug March 27 to treat patients with relapsing forms of the disease. Labeling includes data from one trial that showed patients on Tecfidera experienced disability progression less often.
The EMA’s CHMP has given the nod to Sanofi’s Aubagio and Biogen Idec’s Tecfidera for multiple sclerosis, setting the scene for a European three-way battle with Novartis’ Gilenya in the coming months.